BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Must-See Attractions in Washington, D.C. - 2My Enterprising Excursion: Building a Startup
- 3Air Force made critical errors during October 7 massacre, investigator says
- 4'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 5First part of major new German-Danish tunnel cleared for lowering
- Novo and Lilly cut prices of weight-loss drugs in China
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- The race to mine the moon is on – and it urgently needs some clear international rules
- Email Promoting Instruments for Compelling Efforts
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- The most effective method to Refresh the Infotainment Framework in the Volvo XC40
- The Fragrant Small Tree Birds & Pollinators Love With Stunning Flowers In Summer
- Magnetic fossils may reveal ancient creature's internal 'GPS system'
- Tributes pour in for MIT professor Nuno Loureiro amid unresolved shooting case
